Novel Antibody-Drug Conjugate Shows Survival Benefit in Advanced Lung Cancer

A first-in-class bispecific antibody-drug conjugate nearly doubled progression-free survival compared with standard chemotherapy in patients with advanced non-small cell lung cancer carrying specific genetic mutations, according to clinical trial findings.

Phase III Trial Results

The PANKU-Lung01 phase III trial evaluated the treatment izalontamab brengitecan in patients with EGFR-mutated advanced non-small cell lung cancer whose disease had progressed after taking third-generation EGFR tyrosine kinase inhibitors. Presented at the European Society for Medical Oncology annual congress in Madrid and published in The Lancet, the study included 432 participants across 73 sites in China.

Researchers reported that the median progression-free survival reached 11.1 months for patients receiving the novel drug, compared with 5.7 months for those treated with standard platinum-based chemotherapy. Confirmed objective response rates reached 60.2% in the experimental arm versus 34.5% in the chemotherapy group. Additionally, the median duration of response was 10.5 months compared to 5.7 months.

While overall survival data remained immature at the time of reporting, interim estimates favored the investigational treatment. The trial was led by Li Zhang of the Sun Yat-sen University Cancer Center in Guangzhou.

Safety and Adverse Events

The safety evaluation indicated that grade 3 or higher treatment-related adverse events occurred in 79% of patients receiving the novel therapy and 62% of those receiving chemotherapy. Serious treatment-related adverse events were reported in 43% and 19% of the respective cohorts.

• Neutrophil count decreases occurred in 46% of the investigational group versus 37% of the chemotherapy group.
• White blood cell count decreases were documented in 42% compared to 20%.
• Platelet count decreases affected 38% of patients in the novel drug arm versus 21% in the control arm.
• Anemia was observed in 33% versus 18% of participants.

Febrile neutropenia developed in 6% of patients receiving the antibody-drug conjugate and none in the chemotherapy cohort. Investigators noted that the overall safety profile remained manageable through standard supportive care measures, including dose adjustments, and treatment discontinuation rates due to adverse events remained low at 2% in both groups.

Expert Context and Limitations

Invited discussant Simon Ekman of the Karolinska University Hospital in Stockholm emphasized that while the dual-targeting approach directed at EGFR and HER3 addresses resistance mechanisms, further investigation is warranted. Experts highlighted the need for expanded biomarker research to refine patient selection, deeper analysis of central nervous system metastases, and clarity regarding optimal treatment sequences and combinations. Additional global registration studies are currently underway to further evaluate the agent across broader clinical settings.